Overview

Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity

Status:
NOT_YET_RECRUITING

Trial end date:
2025-08-01

Target enrollment:

Participant gender:

Summary

This is a randomized controlled clinical trial that aims to evaluate the safety and efficacy of Dapagliflozin as a cardioprotective in doxorubicin-induced cardiotoxicity in breast cancer patients.

Phase:

PHASE2

Details

Lead Sponsor:

Tanta University

Treatments:

dapagliflozin